P2.09-35 Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China

Epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations are generally associated with poor prognosis and resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (aNSCLC). In the single-arm CHRYSALIS study (NCT02609776), patients with aNSCLC and EGFR Exon20ins demonstrated durable responses to amivantamab, a bispecific antibody targeting EGFR and mesenchymal epithelial transition factor (MET) with immune-directing activity.